Nasdaq · Healthcare
SCYNEXIS INC (SCYX)
As-reported financials and recent SEC filings for SCYNEXIS INC, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$20.6M
Net income
$-8.6M
Net margin
-41.8%
Diluted EPS
$-0.17
ROE
-17.4%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $20.6M | $3.7M | $140.1M | $5.1M | $13.2M |
| Gross profit | — | — | — | — | — |
| Operating income | $-16.1M | $-37.1M | $72.7M | $-85.8M | $-60.8M |
| Net income | $-8.6M | $-21.3M | $67.0M | $-62.8M | $-32.9M |
| Diluted EPS | $-0.17 | $-0.44 | $1.39 | $-1.47 | $-1.25 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-30
View on EDGAR →42026-06-30
View on EDGAR →42026-06-30
View on EDGAR →42026-06-30
View on EDGAR →42026-06-30
View on EDGAR →8-K2026-06-26
View on EDGAR →8-K2026-05-29
View on EDGAR →8-K2026-05-22
View on EDGAR →Largest Healthcare peers
Go deeper on SCYX
Search SCYNEXIS INC’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.